Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIllumina Inc

Illumina Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
238.21 USD 0.00(0%)
Last update at 2026-11-03T21:00:00Z
VOLUME
2206641
Market Cap
16731.28M

Momentum Score

…

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
229.07
Low
241.85
High
52 Week Price Range
89.00
Low
213.12
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Illumina makes DNA sequencing systems, consumables and analytics used in research and clinical genomics. Long-term growth drivers include broader clinical adoption of genomics, recurring consumables tied to its installed base and periodic platform upgrades which may benefit revenue visibility. The company’s market leadership and high switching costs could support durable cashflows.
Key risks include customer and product-concentration and cyclicality of capital-equipment sales, intense competition and pricing pressure, and exposure to patent, regulatory and legal disputes.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
238.21
Dividend Yield
-
Revenue TTM
4493.00M
Revenue Per Share
28.39
Gross Profit TTM
3145.00M
Debt / Equity
0.39
ROE
-20.76%
Net Debt
1214.00M
ROCE
-48.93%
Diluted EPS TTM
-8.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -4336.00M 884.00M 856.00M 1118.00M 894.00M
Minority interest - 0.00M 0.00M -12.00M -44.00M
Net income -4404.00M 762.00M 656.00M 1002.00M 826.00M
Selling general administrative 1297.00M 2092.00M 941.00M 835.00M 794.00M
Gross profit 2972.00M 3154.00M 2203.00M 2467.00M 2300.00M
Reconciled depreciation 394.00M 251.00M 187.00M 188.00M 179.00M
Ebit -4179.00M -123.00M 393.00M 985.00M 704.00M
Ebitda -3785.00M 128.00M 580.00M 1173.00M 883.00M
Depreciation and amortization 394.00M 251.00M 187.00M 188.00M 179.00M
Non operating income net other -157.00M 1068.00M 325.00M 185.00M 68.00M
Operating income -4179.00M -123.00M 393.00M 985.00M 883.00M
Other operating expenses 4230.00M 4649.00M 2659.00M 2558.00M 2450.00M
Interest expense 26.00M 61.00M 49.00M 52.00M 57.00M
Tax provision 68.00M 122.00M 200.00M 128.00M 112.00M
Interest income 11.00M 919.00M 41.00M 75.00M 44.00M
Net interest income -15.00M -61.00M -8.00M 23.00M -13.00M
Extraordinary items - - - - -11.00M
Non recurring 4533.00M - - - -
Income tax expense 68.00M 122.00M 200.00M 128.00M 112.00M
Total revenue 4584.00M 4526.00M 3239.00M 3543.00M 3333.00M
Total operating expenses 7151.00M 3277.00M 1623.00M 1482.00M 1417.00M
Cost of revenue 1612.00M 1372.00M 1036.00M 1076.00M 1033.00M
Total other income expense net -8829.00M 1007.00M 463.00M 133.00M 11.00M
Net income from continuing ops -4404.00M 762.00M 656.00M 990.00M 782.00M
Net income applicable to common shares -4404.00M 762.00M 656.00M 1002.00M 826.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 10111.00M 12252.00M 15217.00M 7585.00M 7316.00M
Intangible assets 2993.00M 3285.00M 3250.00M 142.00M 145.00M
Other current assets 216.00M 285.00M 295.00M 152.00M 105.00M
Total liab 4366.00M 5653.00M 4477.00M 2891.00M 2703.00M
Total stockholder equity 5745.00M 6599.00M 10740.00M 4694.00M 4613.00M
Deferred long term liab - 705.00M 705.00M - -
Other current liab 987.00M 987.00M 456.00M 355.00M 304.00M
Common stock 2.00M 2.00M 2.00M 2.00M 2.00M
Capital stock 2.00M 2.00M 2.00M 2.00M 2.00M
Retained earnings -19.00M 1142.00M 5485.00M 4723.00M 4067.00M
Other liab - 649.00M 915.00M 303.00M 202.00M
Good will 2545.00M 3239.00M 7113.00M 897.00M 824.00M
Other assets - 212.00M 445.00M 609.00M 179.00M
Cash 1048.00M 2011.00M 1232.00M 1810.00M 2042.00M
Cash and equivalents - 2011.00M 1232.00M 1810.00M -
Total current liabilities 1570.00M 2773.00M 1093.00M 1244.00M 665.00M
Current deferred revenue 252.00M 245.00M 234.00M 186.00M 167.00M
Net debt 1214.00M 1468.00M 1237.00M 45.00M -206.00M
Short term debt 86.00M 1248.00M 71.00M 511.00M 45.00M
Short long term debt - 1248.00M - 511.00M -
Short long term debt total 2262.00M 3479.00M 2469.00M 1855.00M 1836.00M
Other stockholder equity 5763.00M 5452.00M 5236.00M -33.00M 539.00M
Property plant equipment - 1091.00M 1696.00M 922.00M 889.00M
Total current assets 2609.00M 3561.00M 2713.00M 4483.00M 4451.00M
Long term investments - - - - 273.00M
Net tangible assets - 4058.00M 377.00M 4326.00M 4339.00M
Short term investments 6.00M 26.00M 107.00M 1662.00M 1372.00M
Net receivables 752.00M 671.00M 648.00M 487.00M 573.00M
Long term debt 1489.00M 1487.00M 1695.00M 673.00M 1141.00M
Inventory 587.00M 568.00M 431.00M 372.00M 359.00M
Accounts payable 245.00M 293.00M 332.00M 192.00M 149.00M
Accumulated other comprehensive income -1.00M 3.00M 17.00M 2.00M 5.00M
Common stock total equity - 2.00M 2.00M 2.00M 2.00M
Retained earnings total equity - 1142.00M 5485.00M 4723.00M 4067.00M
Treasury stock - - -3702.00M -3848.00M -3021.00M
Non currrent assets other 217.00M 423.00M 445.00M 589.00M 388.00M
Non current assets total 7502.00M 8691.00M 12504.00M 3102.00M 2865.00M
Capital lease obligations 773.00M 744.00M 774.00M 671.00M 740.00M
Long term debt total - 1487.00M 1695.00M 673.00M 1141.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -591.00M -1069.00M -143.00M 1003.00M -1402.00M
Change to liabilities 324.00M 174.00M 60.00M -112.00M 144.00M
Total cashflows from investing activities -591.00M -1069.00M -554.00M 745.00M -1813.00M
Net borrowings 991.00M 471.00M 471.00M -550.00M 731.00M
Total cash from financing activities 1000.00M -51.00M -766.00M -897.00M 594.00M
Change to operating activities 389.00M 10.00M -44.00M -126.00M 95.00M
Net income -4404.00M 762.00M 656.00M 990.00M 782.00M
Change in cash 779.00M -578.00M -232.00M 898.00M -81.00M
Begin period cash flow 1232.00M 1810.00M 2042.00M 1144.00M 1225.00M
End period cash flow 2011.00M 1232.00M 1810.00M 2042.00M 1144.00M
Total cash from operating activities 392.00M 545.00M 1080.00M 1051.00M 1142.00M
Issuance of capital stock 63.00M 60.00M 61.00M 59.00M 46.00M
Depreciation 394.00M 251.00M 187.00M 188.00M 179.00M
Other cashflows from investing activities -305.00M -1069.00M -222.00M -49.00M -115.00M
Dividends paid - - - - 735.00M
Change to inventory -135.00M -58.00M -12.00M 25.00M -53.00M
Change to account receivables -12.00M -164.00M 89.00M -58.00M -105.00M
Sale purchase of stock 63.00M 60.00M -736.00M -324.00M -201.00M
Other cashflows from financing activities 937.00M 406.00M -91.00M -82.00M 1488.00M
Change to netincome 4069.00M -288.00M 124.00M 105.00M 158.00M
Capital expenditures 466.00M 208.00M 189.00M 209.00M 296.00M
Change receivables -12.00M -164.00M 89.00M -58.00M -105.00M
Cash flows other operating 156.00M -264.00M -64.00M -133.00M -4.00M
Exchange rate changes - - - - -4.00M
Cash and cash equivalents changes 801.00M -575.00M -240.00M 899.00M -81.00M
Change in working capital 204.00M -152.00M 73.00M -194.00M -18.00M
Stock based compensation 366.00M 754.00M 194.00M 194.00M 193.00M
Other non cash items 3855.00M -994.00M -147.00M -138.00M 24.00M
Free cash flow -74.00M 337.00M 891.00M 842.00M 846.00M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ILMN
Illumina Inc		 -
-%		 238.21 - 129.87 4.49 3.52 4.76 -35.27
TMO
Thermo Fisher Scientific Inc		 15.69
2.30%		 698.34 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 2.14
0.94%		 230.11 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 23.25 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.81
3.50%		 22.35 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

5200 Illumina Way, San Diego, CA, United States, 92122

858 202 4500

https://www.illumina.com

10590

Name Title Year Born
Mr. Francis A. deSouza CEO & Director 1971
Dr. Alexander Aravanis M.D., Ph.D. CTO & Head of Research and Product Devel. 1977
Mr. Charles E. Dadswell Sr. VP, Gen. Counsel & Sec. 1959
Ms. Susan H. Tousi Chief Commercial Officer 1969
Stephanie Campos Pres NA
Dr. Joydeep Goswami M.B.A., Ph.D. Chief Strategy & Corp. Devel. Officer and Interim CFO 1971
Mr. Kevin Carl Pegels Chief of Global Operations NA
Mr. Scott Ericksen VP & Chief Accounting Officer 1972
Ms. Carissa Rollins Chief Information Officer NA
Ms. Sallilyn Schwartz VP of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…